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Purpose: This study compared health care resource
utilization (HCRU), costs, and persistence among
patients newly diagnosed as having nonvalvular atrial
ﬁbrillation (NVAF) and newly treated with dabigatran
versus warfarin.
Methods: This retrospective claims-based study
used data from a large US managed care organization.
The earliest claim for dabigatran or warfarin during
October 1, 2010 through October 31, 2011 was the
index date, with cohort assignment based on index
medication. Evidence of newly diagnosed NVAF
within 30 days before the index date and no claims
for oral anticoagulants during the 12-month preindex
period were required. Cohorts were matched using
propensity scores. Per-patient-per-month HCRU,
costs, and persistence were calculated during the
variable follow-up period of up to 12 months after
the index date. Descriptive and multivariable analyses
were used to examine differences in outcomes.
Findings: After matching, 869 patients per cohort
were identiﬁed (mean age, 67.8 years; 40.4% female).
Compared with warfarin, dabigatran had fewer per-
patient-per-month emergency department (0.10 vs 0.13,
P ¼ 0.010), ofﬁce (1.98 vs 2.96, P o 0.001), and
outpatient (1.05 vs 1.48, P o 0.001) visits. Despite
higher mean pharmacy costs for dabigatran (Po 0.001),
mean total health care (P ¼ 0.309) and medical costs
(P ¼ 0.568) were similar to warfarin. Persistence was
higher with dabigatran versus warfarin (median, 204 vs
161 days; mean, 213.7 vs 195.5 days, P ¼ 0.001).
Implications: Among patients newly diagnosed as
having NVAF, those newly treated with dabigatran
had lower HCRU, higher persistence, and similar total
health care costs compared with those treated withMarch 2016warfarin. (Clin Ther. 2016;38:545–556) & 2016 The
Authors. Published by Elsevier HS Journals, Inc.
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care resource use, persistence, warfarin.INTRODUCTION
Atrial ﬁbrillation (AF) is the most common clinical
arrhythmia and a major cause of stroke. In the United
States alone, an estimated 1 in 4 adults 40 years and
older will develop AF during their lifetime,1 placing
them at 4- to 5-fold higher risk of stroke.2 Strokes
attributable to AF are associated with greater
mortality, morbidity, and risk of recurrence than
non-AF strokes.3 The annual incremental cost of AF
in the United States is estimated at $8705 per patient
(2008 US dollars), reﬂecting greater use of both
inpatient and outpatient services.4 Extrapolated to
the 2010 US population, the national incremental
burden attributable to AF is in the range of $6
billion to $21 billion annually (2008 US dollars).4
Warfarin, a vitamin K antagonist, is an oral anti-
coagulant (OAC) effective in reducing stroke risk in
patients with AF.5 However, warfarin has a narrow
therapeutic range, requiring regular blood monitoring
and dose adjustments to maintain the target
international normalized ratio (INR) within 2.0 to
3.0.6 US patients with AF maintain an INR within the545
Study Period: October 1, 2009 through October 31, 2012
Patient Identification Period:
October 1, 2010 through October 31, 2011
Index Date
October 1, 2009 October 1, 2010 October 31, 2011 October 31, 2012
Preindex period (12 months) Follow-up period (up to 12 months)
Figure 1. Study design.
Clinical Therapeuticstherapeutic range a mean of 55% of the time.7
Underanticoagulation, as evidenced by an INR
o2.0, increases the risk and severity of ischemic
stroke,8,9 whereas overanticoagulation (INR 43.0)
increases bleeding risk.9 There are considerable drug
and food interactions with warfarin,10 which can also
compromise INR control. Both INR testing and the
consequences of poor INR control consume
considerable health care resources.11–13
Dabigatran,14 a direct thrombin inhibitor, is an OAC
approved by the Food and Drug Administration in the
United States in October 2010 to reduce the risk of
stroke and systemic embolism in patients with non-
valvular atrial ﬁbrillation (NVAF), which represents
approximately 95% of AF cases.15 Dabigatran offers
several advantages over warfarin. First, INR testing is
not required to maintain therapeutic levels. Next, in the
pivotal Randomized Evaluation of Long-Term Antico-
agulant Therapy clinical trial, dabigatran was associated
with lower rates of stroke and systemic embolism
compared with adjusted-dose warfarin.16 Furthermore,
in real-world clinical practice, patients newly diagnosed
as having NVAF who initiate OAC therapy with
dabigatran were more likely to persist with therapy than
their counterparts initiating warfarin therapy.17
However, the effect of these clinical advantages of
dabigatran over warfarin on health care resource
utilization (HCRU) in clinical practice has not been
well characterized. The objective of this study was to
compare real-world HCRU and costs among patients
newly diagnosed as having NVAF who were newly
treated with dabigatran versus warfarin. We also eval-
uated persistence to each OAC therapy during the ﬁrst
year of treatment.METHODS
Study Design and Data Source
This retrospective claims-based study used medical,
pharmacy, and enrollment data from a large US man-
aged care organization afﬁliated with Optum, Inc.
The patient index date was identiﬁed based on the
date of initiation of dabigatran or warfarin treatment.
Because dabigatran was approved in October 2010,
the patient identiﬁcation period began on October 1,
2010 continuing through October 31, 2011. Data
extracted for each patient covered 12 months before
the index date and up to 12 months after the index
date; therefore, the full study period spanned October5461, 2009 through October 31, 2012 (Figure 1). During
the patient identiﬁcation period, the database contained
15,316,248 commercial and Medicare Advantage
Prescription Drug coverage enrollees with medical and
pharmacy beneﬁts. Medical claims data used for this
study included International Classiﬁcation of Disease,
Ninth Revision, Clinical Modiﬁcation (ICD-9-CM)
diagnosis and procedure codes, Healthcare Common
Procedure Coding System codes, revenue codes, and
paid amounts (combined health plan plus patient paid
amounts). Pharmacy claims data used for this study
included National Drug Codes for ﬁlled prescriptions,
days supplied, quantity of drug supplied, and paid
amounts. All study data were accessed using
techniques compliant with the Health Insurance
Portability and Accountability Act.Patient Identification and Study Cohorts
The study sample comprised patients newly diag-
nosed as having NVAF and newly treated
with dabigatran or warfarin. The index date was
deﬁned as the ﬁrst pharmacy claim for dabigatran or
warfarin (index OAC) during the patient identiﬁcation
period.
Patients were identiﬁed for inclusion in the study in
a sequential manner. First, all patients were required
to have Z1 inpatient claim (ie, medical claim asso-
ciated with inpatient stay) or Z2 ofﬁce visit or
emergency department (ED) claims (ie, medical claims
associated with ofﬁce or ED visits or a combination
thereof) with a diagnosis code for AF (ICD-9-CM
code 427.31 in any position) in the 12 months before
the index date.4,17–19 Patients were also required to
have continuous health plan enrollment with medical
and pharmacy beneﬁts for 12 months before the index
date (deﬁned as the preindex period) and up to 12Volume 38 Number 3
T. Bancroft et al.months after (and including) the index date (deﬁned as
the follow-up period). End of follow-up was deﬁned
as the earliest of health plan disenrollment, medication
discontinuation (or switch) from the index OAC,
death, 12 months after the index date, or end of study
period (October 31, 2012). The earliest medical claim
with diagnosis code for AF during the preindex period
was deﬁned as the ﬁrst AF claim.
To distinguish NVAF from AF, patients with Z1
medical claim with evidence of valvular heart disease
(Supplemental Table I) were excluded. In the interest
of excluding transient and secondary NVAF, patients
with Z1 medical claim with evidence of cardiac
surgery, myocarditis, pericarditis, or pulmonary
embolism (Supplemental Table I) within 30 days
before the ﬁrst AF claim were excluded. In addition,
patients o18 years old on the index date and patients
with Z1 medical claim with evidence of
hyperthyroidism (Supplemental Table I) during the
preindex period were excluded. The remaining
patients were then required to have Z2 pharmacy
claims on separate dates for the index OAC
(dabigatran or warfarin) during the follow-up period,
including the pharmacy claim for the OAC on the
index date.
Finally, the criteria of newly diagnosed NVAF and
newly treated with dabigatran or warfarin were
applied: newly diagnosed NVAF was deﬁned as the
occurrence of ﬁrst AF claim within 30 days before the
index date; patients with claim(s) for AF that occurred
before 30 days from the index date (ie, days 31–365
before the index date) were excluded. Newly treated
was deﬁned as no pharmacy claims for any OAC
(dabigatran, rivaroxaban, or warfarin) during the
preindex period. Patients were then assigned to either
the dabigatran or warfarin cohort according to the
index OAC.
Patient Characteristics
Age, sex, geographic location, and health plan type
(commercial or Medicare Advantage Prescription
Drug coverage) were reported as of the index date.
The following clinical indexes were calculated during
the preindex period: Deyo-Charlson comorbidity
score,20 CHADS2
21 and CHA2DS2-VASc
22 stroke
risk scores, and HEMORR2HAGES bleeding risk
score.23 The Deyo-Charlson comorbidity score is a
predictor of mortality risk deﬁned by 17 medical
conditions. The CHADS2 score is a predictor of strokeMarch 2016risk that incorporates patient age (474 years) and
history of chronic heart failure, hypertension, diabetes
mellitus, and stroke/transient ischemic attack as risk
factors; the CHA2DS2-VASc score includes 3 addi-
tional risk factors (female sex, age 65–74 years, and
vascular disease). The HEMORR2HAGES score is a
predictor of bleeding risk according to patient age
(475 years), medical history (hepatic or renal disease,
alcohol abuse, malignant tumor, reduced platelet
count or dysfunction, rebleeding risk, uncontrolled
hypertension, anemia, stroke), genetic factors, and
excessive fall risk. The presence or absence of clin-
ically relevant conditions or events during the prein-
dex period was identiﬁed based on ICD-9-CM
diagnosis and procedure codes from preindex medical
claims (Supplemental Table I). Preindex medication
use was determined by pharmacy and medical claims
and categorized as the presence or absence of any
medication and as counts of individual medications or
medication classes (Supplemental Table II). Health
care costs (ie, medical and pharmacy) were calculated
for the preindex period. All-cause total health care
costs represented the sum of medical and pharmacy
costs; all costs were inﬂation adjusted to 2012 US
dollars.24
Outcomes
Persistence to index OAC represented the time to
discontinuation or switch of index OAC. Discontinu-
ation was deﬁned as failure to reﬁll (ie, an absence of a
pharmacy claim for the index exposure within 30 days
[permissible gap] of the run-out date of the previous
claim for the index exposure). Patients who did not
discontinue or switch index OAC were right-censored
at the earliest of: health plan disenrollment, death, end
of 12-month follow-up, or end of study period
(October 31, 2012). Although warfarin treatment
discontinuation has been previously deﬁned by gaps
in both prescription ﬁll dates and INR testing,25,26 a
30-day medication gap is a sensitive measure of
discontinuation.17
Both HCRU and costs were calculated for the
follow-up period and censored on the date of dis-
continuation or switch of index OAC (if either
occurred). Because of variable length follow-up,
HCRU and costs were reported as per-patient-per-
month (PPPM). All-cause HCRU was deﬁned as the
counts of health care encounters, categorized as
inpatient stay, ED visit, outpatient visit, and ofﬁce547
Clinical Therapeuticsvisit. All-cause health care costs were calculated as
total costs (sum of medical and pharmacy costs),
medical costs, and pharmacy costs; all costs were
inﬂation adjusted to 2012 US dollars.24
Propensity Score Matching
Patients in the dabigatran and warfarin cohorts
were 1:1 nearest neighbor matched using propensity
score matching (PSM) with a caliper of 0.2 of the SD
of the estimated logit. Propensity scores were calcu-
lated by logistic regression modeling with the follow-
ing predictor variables: age, sex, health plan type,
geographic location, and index month and preindex
characteristics, namely, Deyo-Charlson comorbidity
score, CHADS2 score, HEMORR2HAGES score,
presence or absence of comorbidities (Supplemental
Table I), all-cause medical costs, all-cause pharmacy
costs, index prescriber specialty, time from ﬁrst AF
claim to index date, and presence or absence of
medication use (Supplemental Table II).
Statistical Analysis
Between-cohort comparisons of pre-PSM, pre-
index characteristics were conducted with 2-sample
t tests with Satterthwaite adjustment where appropri-
ate (continuous variables) and χ2 tests (categorical
variables). Between-cohort comparisons of post-PSM,
preindex characteristics and outcomes during follow-
up were conducted with paired t tests (continuous
variables) and Rao-Scott tests (categorical variables).
Multivariable regression models adjusting for prein-
dex characteristics were constructed to examine cohort
differences in follow-up all-cause health care costs and
time to index therapy discontinuation or switch. Time to
index therapy discontinuation was modeled with Cox
proportional hazards. The estimated time to therapy
discontinuation was also described graphically using the
Kaplan-Meier estimator of the cumulative hazard rate.
All-cause total health care, medical, and pharmacy costs
were modeled with Lin’s regression,27,28 which accounts
for censored follow-up time and cost accumulation at
multiple intervals. With this method, the follow-up
period is partitioned into twelve 30-day intervals during
which costs are accumulated and the cost within each
30-day interval is weighted by the probability of survival
during each interval. The SEs for 12-month adjusted
costs are based on 1000 bootstrapped samples.
All regression models included index OAC and the
following adjustment variables: age, sex, geographic548location, health plan type, presence or absence of
preindex stroke, Deyo-Charlson comorbidity score,
CHA2DS2-VASc score, HEMORR2HAGES score, and
log-transformed preindex all-cause total health care
costs. In addition, other covariates serving as adjust-
ment variables only were included based on stepwise
selection using P = 0.05 for both entry and retention in
the model. Adjustment variables subject to stepwise
selection were index prescriber specialty (cardiology or
other) and the following preindex characteristics: pres-
ence or absence of selected comorbid conditions (cancer,
rheumatoid arthritis, multiple sclerosis, coronary artery
disease, acute myocardial infarction, cardiomyopathy,
transient ischemic attack, ischemic stroke, heart failure,
atrial ﬂutter, hypertension, peripheral artery disease,
liver disease, renal disease, chronic obstructive pulmo-
nary disease or emphysema, hypothyroidism, diabetes,
peptic ulcer or gastroesophageal reﬂux disease, venous
thromboembolism, hyperlipidemia, Human Immunode-
ﬁciency Virus (HIV) infection, bone marrow disease,
coagulopathy, dyspepsia, bleeding), the count of con-
comitant medication classes, pharmacy claims, all-cause
outpatient visits, all-cause ofﬁce visits, all-cause ED
visits, and total length (days) of all inpatient stays.RESULTS
Patient Identification and Characteristics
A total of 49,448 patients with NVAF and Z2
claims for either dabigatran (7013 patients) or war-
farin (42,435 patients) on or after the index date were
identiﬁed (Figure 2). Among these patients, 1010 were
newly diagnosed as having NVAF and newly treated
with dabigatran, and 3200 were newly diagnosed as
having NVAF and newly treated with warfarin. After
PSM, 869 patients in each cohort were retained.
The pre- and post-PSM characteristics of each
cohort for key matching variables are given in Table I;
the full complement of matching variables and other
characteristics of interest are given in Supplemental
Table III. Among all matched patients, the mean age
was 67.8 years, 40.4% were female, and most patients
(64.7%) had commercial insurance. The mean time
from ﬁrst AF claim to index date was just 41 week
and similar between cohorts (8.7 and 8.4 days for
dabigatran and warfarin, respectively; P¼0.343). The
mean Deyo-Charlson, CHADS2, CHA2DS2-VASc, and
HEMORR2HAGES scores were also similar between
cohorts. After matching, clinical characteristics wereVolume 38 Number 3
≥ 1 inpatient; otherwise ≥2 office or ED visits
 (or a combination of both) with AF diagnosis
 during 12-month preindex period*
          (n=187,927)
    Continuous enrollment with medical and
pharmacy benefits for at least 12 months before
the index date and up to 12 month after the index date
(n=134,570)
Exclusions
(n=287)
Age<18 years, missing sex or region
Hyperthyroidism during the 12-month preindex
period (n=2645)
Cardiac surgery, pericarditis, myocarditis, or
pulmonary embolism within 30 days before
AF diagnosis (n=3424)
Valvular heart disease during the 12-month pre
index period (n=2444)
Valid enrollment data (n=14)
NVAF patients meeting initial eligibility criteria
(n=125,756)
≥ 2 claims for dabigatran or warfarin on or after the
index date
(n=49,448)
Newly diagnosed NVAF and newly treated with
oral anticoagulant
(n=4210)
Dabigatran
(n=1010)
Warfarin
(n=3200)
Figure 2. Patient sample identification. AF ¼
indicates atrial fibrillation; ED ¼
emergency department; NVAF ¼ non-
valvular atrial fibrillation. *Index date
is first pharmacy claim for warfarin or
dabigatran (index oral anticoagulant)
during the patient identification per-
iod (October 1, 2010 through Octo-
ber 31, 2011). †Newly diagnosed
NVAF was defined as the occurrence
of the first AF claim within 30 days
before the index date, and newly
treated was defined as no claims for
oral anticoagulant (dabigatran, rivar-
oxaban, or warfarin) during the 12-
month preindex period.
T. Bancroft et al.similar between cohorts for all matched variables with
the exception of preindex bleeding. Compared with the
warfarin cohort, a slightly higher proportion of
dabigatran-treated patients had preindex bleeding
(6.2% vs. 4.0%, P ¼ 0.037).
HCRU and Costs
All-cause HCRU (PPPM) of the dabigatran and
warfarin cohorts during follow-up is given in Table II.March 2016The dabigatran cohort had signiﬁcantly fewer ED
visits (0.10 vs 0.13, P ¼ 0.010), ofﬁce visits (1.98 vs
2.96, P o 0.001), and outpatient visits (1.05 vs 1.48,
P o 0.001) than the warfarin cohort. The mean
counts of inpatient stays were lower for the
dabigatran cohort, but the difference was not
statistically signiﬁcant between cohorts (P ¼ 0.093).
Adjusted 12-month, mean all-cause health care
costs are presented in Table III. Similar to the
unadjusted cost results, although pharmacy costs
were higher for the dabigatran cohort (P o 0.001),
total health care (P ¼ 0.318) and medical (P ¼ 0.750)
costs were similar for both cohorts.
Persistence
Measures of persistence with index OAC are given
in Table IV and Figure 3. Compared with the warfarin
cohort, a lesser proportion of patients in the dabigatran
cohort discontinued therapy (51.9% vs 61.6%, P o
0.001), and dabigatran-treated patients continued to
receive therapy longer (median days, 204.0 vs 161.0;
mean days, 213.7 vs 195.5; P ¼ 0.001). The Kaplan-
Meier probabilities of persistence were greater for the
dabigatran cohort throughout the 365-day follow-up
period (P o 0.001). In the adjusted Cox proportional
hazards analysis, the dabigatran cohort had 21.5%
lower risk of treatment discontinuation (hazard ratio,
0.785; 95% CI, 0.692-0.890; P o 0.001).DISCUSSION
Our results provide important insights into the real-
world HCRU and costs of patients newly diagnosed as
having NVAF who are newly treated with dabigatran
versus warfarin. Patients newly treated with dabiga-
tran had less all-cause HCRU than patients taking
warfarin. Patients initiating OAC therapy with dabi-
gatran were also more likely to be persistent with
therapy in the ﬁrst year of treatment than those
patients taking warfarin.
Patients newly treated with dabigatran had lower
mean all-cause HCRU in the ambulatory setting than
warfarin-treated patients. The dabigatran cohort in-
curred a mean of 33% fewer ofﬁce and 29% fewer
outpatient visits. Higher ambulatory service utilization
among warfarin-treated patients likely reﬂects in part
the incremental burden of regular INR testing and
dose adjustments for patients managed with warfarin.
A recent study of 5 US claims databases indicated that549
Table I. Patient demographic and clinical characteristics before and after PSM.
Characteristic*
Before PSM After PSM
Dabigatran
(n ¼ 1010)
Warfarin
(n ¼ 3200) P value†
Dabigatran
(n ¼ 869)
Warfarin
(n ¼ 869) P value‡
Age, mean (SD), y 66.9 (11.3) 72.0 (11.2) o0.001 67.7 (11.5) 67.9 (11.6) 0.698
Female, no. (%) 397 (39.3) 1477 (46.2) o0.001 345 (39.7) 357 (41.1) 0.547
Geographic location, no. (%)
Northeast 115 (11.4) 341 (10.7) 0.515 100 (11.5) 87 (10.0) 0.323
Midwest 261 (25.8) 1265 (39.5) o0.001 248 (28.5) 245 (28.2) 0.870
South 528 (52.3) 1260 (39.4) o0.001 425 (48.9) 427 (49.1) 0.924
West 106 (10.5) 334 (10.4) 0.958 96 (11.1) 110 (12.7) 0.305
Health plan type, no. (%)
Commercial 692 (68.5) 1231 (38.5) o0.001 559 (64.3) 566 (65.1) 0.691
MAPD coverage 318 (31.5) 1969 (61.5) o0.001 310 (35.7) 303 (34.9) 0.691
Time from ﬁrst AF claim to index
date, d
Mean (SD) 8.9 (8.1) 8.4 (7.3) 0.084 8.7 (8.0) 8.4 (7.5) 0.343
Median 6.0 6.0 5.0 5.0
Preindex clinical index scores, mean
(SD)
Deyo-Charlson comorbidity index 1.73 (1.80) 2.49 (2.09) o0.001 1.85 (1.84) 1.86 (1.81) 0.967
CHADS2 1.91 (1.24) 2.44 (1.30) o0.001 2.00 (1.24) 2.01 (1.21) 0.903
CHA2DS2-VASc 3.09 (1.76) 3.95 (1.78) o0.001 3.23 (1.77) 3.26 (1.73) 0.749
HEMORR2HAGES 2.28 (1.65) 3.14 (1.99) o0.001 2.41 (1.69) 2.33 (1.58) 0.320
Preindex conditions or events, no. (%)
Hyperlipidemia 699 (69.2) 2248 (70.3) 0.529 605 (69.6) 590 (67.9) 0.444
Diabetes mellitus 304 (30.1) 1184 (37.0) o0.001 271 (31.2) 258 (29.7) 0.495
Heart failure 244 (24.2) 1256 (39.3) o0.001 237 (27.8) 243 (28.0) 0.737
Peptic ulcer or GERD 181 (17.9) 752 (23.5) o0.001 159 (18.3) 169 (19.5) 0.532
COPD or emphysema 180 (17.8) 644 (20.1) 0.108 153 (17.6) 171 (19.7) 0.272
Cardiomyopathy 134 (13.3) 498 (15.6) 0.075 121 (13.9) 125 (14.4) 0.784
Hypertension 127 (12.6) 605 (18.9) o0.001 114 (13.1) 105 (12.1) 0.520
Ischemic stroke 95 (9.4) 403 (12.6) 0.006 85 (9.8) 92 (10.6) 0.574
Transient ischemic attack 78 (7.7) 281 (8.8) 0.294 66 (7.6) 74 (8.5) 0.483
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Table I. (continued).
Characteristic*
Before PSM After PSM
Dabigatran
(n ¼ 1010)
Warfarin
(n ¼ 3200) P value†
Dabigatran
(n ¼ 869)
Warfarin
(n ¼ 869) P value‡
Bleeding 55 (5.5) 340 (10.6) o0.001 54 (6.2) 35 (4.0) 0.037
Venous thromboembolism 14 (1.4) 353 (11.0) o0.001 14 (1.6) 9 (1.0) 0.252
Preindex (12-month) all-cause total
health care costs, mean (SD), $§
16,679 (20,001) 23,826 (32,132) o0.001 17,342 (20,839) 17,578 (21,023) 0.810
Duration of follow-up, d
Mean (SD) 208.2 (129.7) 200.1 (128.9) 0.084 210.6 (130.4) 193.6 (125.4) 0.003
Median 186.5 171.0 194.0 159.0
AF ¼ atrial ﬁbrillation; COPD ¼ chronic obstructive pulmonary disease; GERD ¼ gastroesophageal reﬂux disease; MAPD ¼ Medicare Advantage Prescription Drug;
PSM ¼ propensity score match; SD ¼ standard deviation.
*The following preindex variables were used for PSM: age, sex, plan type, geographic location, index month, Deyo-Charlson comorbidity score, CHADS2 score,
HEMORR2HAGES score, comorbidities (heart failure, diabetes mellitus, cardiomyopathy, COPD or emphysema, hyperlipidemia, peptic ulcer or GERD, stroke or
transient ischemic attack, hypertension, venous thromboembolism, bleeding), index prescriber specialty, time from ﬁrst AF claim to index exposure, and concomitant
medication use (argatroban, unfractionated heparin, enoxaparin, tinzaparin, dalteparin, fondaparinux, β-blockers, calcium channel blockers, diuretics, other
antihypertensives [angiotensin-converting enzyme inhibitors, angiotensin receptor blockers], antihyperlipidemics, corticosteroids, antidiabetics, antiarrhythmics
[amiodarone, propafenone, ﬂecainide, dronedarone, sotalol, dofetilide, disopyramide, quinidine], ketoconazole, antiplatelets, nonsteroidal anti-inﬂammatory
drugs).
†Two-sample t test with Satterthwaite adjustment where appropriate (continuous variables) and χ2 test (categorical variables).
‡Paired t test (continuous variables) and Rao-Scott test (categorical variables).
§All-cause preindex health care costs was not a PSM variable.
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Table II. All-cause HCRU during follow-up.
Visit Type
PPPM Count of HCRU, Mean (SD)*
P†Dabigatran (n ¼ 869) Warfarin (n ¼ 869)
Inpatient stays 0.06 (0.15) 0.07 (0.18) 0.093
ED visits 0.10 (0.27) 0.13 (0.31) 0.010
Ofﬁce visits 1.98 (1.67) 2.96 (2.16) o0.001
Outpatient visits 1.05 (1.42) 1.48 (1.81) o0.001
ED ¼ emergency department; HCRU ¼ health care resource utilization; PPPM ¼ per-patient-per-month.
*Propensity score matched cohorts.
†Paired t test.
Clinical Therapeuticspatients with AF who undergo INR testing have a
mean of 0.5 to 2.0 INR tests per month.29 We also
observed 26% lower mean utilization of all-cause ED
services for dabigatran-treated patients. Greater uti-
lization of ED services may reﬂect suboptimal INR
control among some warfarin-treated patients. The
percentage of time spent outside the INR therapeutic
range among warfarin-treated patients is consider-
able,7,9 and patients with poor anticoagulation con-
trol have worse clinical outcomes, including a higher
risk of stroke and bleeding events, which drive higher
and more costly resource utilization.12,19,30 However,
our results are based on all-cause utilization, and we
cannot ascribe the overall higher HCRU in the
warfarin cohort to speciﬁc events, such as INR testing,
stroke, or bleeding. As expected, all-cause pharmacyTable III. All-cause health care costs during follow-up.
Cost Type
Mean Adjusted 12-M
Dabigatran* (n ¼
Total (medical plus pharmacy) 25,369.89
Medical 19,194.98
Pharmacy 6121.92
*Propensity score matched cohorts.
†The 12-month total health care costs were evaluated using Li
health plan type, and the following preindex characteristics:
disease, Deyo-Charlson comorbidity score, CHA2DS2-VASc score
visits, and all-cause inpatient days.
552costs were higher for the dabigatran cohort, given that
dabigatran is available as a branded medication.
However, all-cause total health care and medical costs
were similar for both treatment cohorts, suggesting that
dabigatran is a cost-neutral alternative to warfarin.
According to the Cox proportional hazards analy-
sis, patients taking dabigatran were 21.5% less likely
to discontinue or switch therapy than warfarin-treated
patients. The Kaplan-Meier probabilities of patients
remaining on therapy at 1 year were 43.4% for the
dabigatran cohort and 33.0% for the warfarin cohort.
Given that dabigatran is a relatively new option in
anticoagulation, there are limited comparator studies
based on large claims databases in the peer-reviewed
literature.17,31 Our results can be most readily com-
pared with the ﬁndings of Zalesak et al,17 whose studyonth All-Cause Health Care Costs, $
P†869) Warfarin* (n ¼ 869)
23,430.14 0.318
19,814.64 0.750
3459.48 o0.001
n’s regression, adjusted for age, sex, geographic location,
ischemic stroke, heart failure, liver disease, bone marrow
, HEMORR2HAGES score, all-cause emergency department
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Table IV. Persistence with dabigatran and warfarin during follow-up.
Variable Dabigatran* (n ¼ 869) Warfarin* (n ¼ 869) P
Discontinued, no. (%) 451 (51.9) 535 (61.6) o0.001‡
Switch, no. (%) 25 (6.0) 38 (4.4) 0.127‡
Persistence, d
Mean (SD) 213.7 (129.6) 195.5 (125.6) 0.001†
Median 204.0 161.0
Kaplan-Meier persistence probability, % o0.001§
90 Days 77.7 74.6
180 Days 61.5 53.9
270 Days 50.7 40.2
365 Days 43.4 33.0
*Propensity score matched cohorts.
†Paired t test.
‡Rao-Scott test.
§Log-rank test.
T. Bancroft et al.methods most closely resembled what we used to
create newly diagnosed and newly treated NVAF
cohorts and to deﬁne persistence. In the study by
Zalesak et al,17 1-year persistence was 50.3% for1.0
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Figure 3. Kaplan-Meier probability of persistence.
March 2016dabigatran versus 24.1% warfarin. Dabigatran persis-
tence was somewhat higher than we observed, which
may be partially a function of differences in patient
preindex characteristics between the 2 studies. For00
n Warfarin
e (d)
Log-rank test P < 0.001
300 365
553
Clinical Therapeuticsexample, younger age and lower stroke risk (CHADS2
score o2) were predictors of nonpersistence to dabi-
gatran in the previous study (which analyzed predic-
tors of nonpersistence separately for each OAC
cohort). The dabigatran cohort in our study was
younger (68 vs 73 years) and had lower mean
CHADS2 scores (2.0 vs 2.3) than the previous study.
However, Zalesak et al17 also observed that higher
Deyo-Charlson comorbidity score and higher bleeding
risk (HEMORR2HAGES score43) were predictive of
nonpersistence to dabigatran, and dabigatran-treated
patients in our study had lower mean Deyo-Charlson
comorbidity scores (1.85 vs 2.5) and slightly lower
HEMORR2HAGES scores (2.4 vs 2.6). Younger age,
lower CHADS2 scores, and bleeding events are also
known risk factors for nonpersistence with warfarin
therapy.32–35 Additional research is needed to deter-
mine the degree to which these patient characteristics
and possibly other factors predict persistence to
dabigatran in clinical practice.
The prevalence of AF is projected to increase 2.5-
to 3-fold between 2000 and 2050.15,36,37 Underutili-
zation of warfarin38 and low persistence rates with
warfarin therapy35 place patients with AF at
considerably greater risk of stroke and the sequelae
of higher HCRU and costs. Our results suggest that
dabigatran offers beneﬁts in terms of lower HCRU
and higher medication persistence, with total health
care costs that are similar to warfarin.
Study Limitations
Certain limitations that are inherent to claims-
based analyses should be considered when interpreting
the results of this study. The entire medical history of
a patient is not available in claims databases, and the
information that was captured in this study was
limited to the study period. The presence of a
diagnostic code on a medical claim is not proof
positive of the presence of disease. To strengthen the
selection of patients with evidence of AF, we required
either an inpatient claim or Z2 ofﬁce or ED claims
with diagnosis code for AF. We used PSM to max-
imize the balance in relevant patient characteristics
between the dabigatran and warfarin cohorts; how-
ever, there may have been other unmeasured or
unidentiﬁed factors that were not balanced among
cohorts and could have inﬂuenced the outcomes.
Unlike dabigatran, warfarin use may be subject to
frequent dose adjustments based on INR test results,554which may shorten or lengthen the duration of
medication supply available in a single prescription
ﬁll. Our estimates of persistence are based on the
earliest gap in index OAC supply 430 days. It is
possible that persistence was overestimated or under-
estimated using this technique; however, previous
research has found that 89% of warfarin and 95%
of dabigatran medication gaps wereo30 days17; thus,
we would expect the degree of overestimation and
underestimation to be similar between cohorts.
Furthermore, pharmacy claims do not indicate
whether the medication was taken or taken as
prescribed. Finally, our results are based on patients
with commercial or Medicare fee-for-service insurance
and may not be generalizable to other populations.CONCLUSIONS
Among patients newly diagnosed as having NVAF and
newly treated with dabigatran or warfarin, those
treated with dabigatran had signiﬁcantly fewer ofﬁce,
outpatient, and ED visits than those taking warfarin.
The all-cause total health care costs were similar among
dabigatran- and warfarin-treated patients. Dabigatran-
treated patients were also more likely to remain per-
sistent and to do so for longer periods than warfarin-
treated patients during the ﬁrst year of treatment.ACKNOWLEDGMENTS
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Tables I–III.Table I. Supplemental codes
Conditions Codes
Conditions used in sample selection
Valvular heart disease ICD-9-CM diagnosis codes (any position): 394.0x, 394.2, 396.0, 396.0
HCPCS codes: 33999, 0257T, 0258T, 0259T, 33405, 33425, 33426,
33427, 33430, 0262T, 33475, 33460, 33463, 33464, 33465
Cardiac surgery ICD-9-CM procedure codes: 00.5x, 35.xx, 36.xx, 37.xx
Myocarditis ICD-9-CM diagnosis codes (any position): 391.2, 422.xx, 074.23, 398.0,
429.0, 032.82, 036.43, 093.82, 130.3
Pericarditis ICD-9-CM diagnosis codes (any position): 391.x, 393, 420.x, 423.2,
0.36.41, 074.21, 093.81, 098.83
Pulmonary embolism ICD-9-CM diagnosis codes (any position): 415.1x
Hyperthyroidism ICD-9-CM diagnosis codes (any position): 242.x
Pre-index conditions/events
Cancer ICD-9-CM diagnosis codes (any position): 140.xx-172.xx, 174.xx-208.xx,
230.xx-231.xx, 233.xx-234.xx
Rheumatoid arthritis ICD-9-CM diagnosis codes (any position): 714.xx
Multiple sclerosis ICD-9-CM diagnosis codes (any position): 340
Coronary artery disease ICD-9-CM diagnosis codes (any position): 411.xx, 412.xx, 413.xx, 414.xx,
429.2
Acute MI ICD-9-CM diagnosis codes (any position): 410.xx
Cardiomyopathya ICD-9-CM diagnosis codes (any position): 425.xx
Ischemic strokea ICD-9-CM diagnosis codes (any position): 433.x1, 434.x1, 436.x
TIAa ICD-9-CM diagnosis codes (any position): 435.x
Heart failurea ICD-9-CM diagnosis codes (any position): 402.x1, 404.x1, 404.x3, 428.xx
Atrial ﬂutter ICD-9-CM diagnosis codes (any position): 427.32
Hypertensiona ICD-9-CM diagnosis codes (any position): 401.x, 402.x0, 403.xx, 404.x0,
404.x2, 405.xx
Peripheral artery disease ICD-9-CM diagnosis codes (any position): 440.xx, 443.xx
Liver disease ICD-9-CM diagnosis codes (any position): 121.1, 423.2, 570-573.xx,
751.62
Renal disease ICD-9-CM diagnosis codes (any position): 580.xx-588.xx, 590.xx-593.xx
COPD/emphysemaa ICD-9-CM diagnosis codes (any position): 490-492.xx, 496
Hypothyroidism ICD-9-CM diagnosis codes (any position): 243-244.x
Diabetesa ICD-9-CM diagnosis codes (any position): 250.xx
Peptic ulcer/GERDa ICD-9-CM diagnosis codes (any position): 530.11, 530.81, 536.2, 536.8,
787.1, 533.xx
Venous thromboembolisma ICD-9-CM diagnosis codes (any position): 415.11, 415.19, 451.1x, 451.2,
451.81, 451.83, 451.84, 451.9,453.4x, 453.8x, 453.9
Hyperlipidemiaa ICD-9-CM diagnosis codes (any position): 272.0–272.4
HIV infection ICD-9-CM diagnosis codes (any position): V08, 042, 079.53
(continued)
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Table I. (continued).
Conditions Codes
Bone Marrow disease ICD-9-CM diagnosis codes (any position): 287.3x, 287.4x, 287.5x, 285.2x,
289.83
Thrombocytopenia ICD-9-CM diagnosis codes (any position): 287.3, 287.4, 287.5
Chronic anemia ICD-9-CM diagnosis codes (any position): 285.2
Myeloﬁbrosis ICD-9-CM diagnosis codes (any position): 289.83
Coagulopathy (hemophilia/ Von
Willebrand disease)
ICD-9-CM diagnosis codes (any position): 286.0-286.9, 287.1,
287.3-287.5
Dyspepsia ICD-9-CM diagnosis codes (any position): 536.8
Bleedinga ICD-9-CM diagnosis codes (primary position only): 455.2, 455.5, 455.8,
456.0, 456.20, 459.0, 530.7, 530.82, 531.0, 531.2, 531.4, 531.6,
532.0, 532.2, 532.4, 532.6, 533.0, 533.2, 533.4, 533.6, 534.0, 534.2,
534.4, 534.6, 535.01, 535.11, 535.21, 535.31, 535.41, 535.51, 535.61,
537.83, 562.02, 562.03, 562.12, 562.13, 568.81, 569.3, 569.85, 578,
599.7, 719.1x, 786.3, 423.0, 593.81, 784.7, 784.8
ICD-9-CM diagnosis codes (any position): 430, 431, 432, 852.0x, 852.2x,
852.4x, 853.0
GERD, gastroesophageal reﬂux disease; HIV, Human Immunodeﬁciency Virus; MI, myocardial infarction; TIA, transient
ischemic attack
aPSM match variables.
Table II. Pre-index medications
Medications Medication Classes
Dabigatran Beta blockersa
Rivaroxaban Calcium channel blockersa
Warfarin Diureticsa
Argatrobana Other antihypertensives (angiotensin-converting-enzyme inhibitors,
angiotensin receptor blockers)a
Unfractionated heparina Antihyperlipidemicsa
Enoxaparina Corticosteroidsa
Tinzaparina Antidiabeticsa
Dalteparina Antiarrhythmics (amiodarone, propafenone, ﬂecainide, dronedarone,
sotalol, dofetilide, disopyramide, quinidine)a
Fondaparinuxa Antiplateletsa
Ketoconazolea Non-steroidal anti-inﬂammatory drugsa
aPSM match variables
Clinical Therapeutics
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Table III. Patient demographic and clinical characteristics before and after PSM for all matching variables and
other comorbid conditions and risk scores
Before PSM After PSM
Characteristic*
Dabigatran
(n¼1,010)
Warfarin
(n¼3,200) P value†
Dabigatran
(n¼869)
Warfarin
(n¼869) P value†
Age, mean (SD) 66.9 (11.3) 72.0 (11.2) o0.001 67.7 (11.5) 67.9 (11.6) 0.698
Age group, n (%)
18-34 4 (0.4) 8 (0.3) 0.448 4 (0.5) 3 (0.4) 0.706
35-44 21 (2.1) 48 (1.5) 0.206 16 (1.8) 19 (2.2) 0.612
45-54 116 (11.5) 187 (5.8) o0.001 96 (11.1) 88 (10.1) 0.530
55-64 306 (30.3) 535 (16.7) o0.001 238 (27.4) 232 (26.7) 0.749
65-74 287 (28.4) 934 (29.2) 0.638 249 (28.7) 249 (28.7) 1.000
75-79 114 (11.3) 555 (17.3) o0.001 109 (12.5) 112 (12.9) 0.826
Z80 162 (16.0) 933 (29.2) o0.001 157 (18.1) 166 (19.1) 0.562
Female, n (%) 397 (39.3) 1,477 (46.2) o0.001 345 (39.7) 357 (41.1) 0.547
Geographic location, n (%)
Northeast 115 (11.4) 341 (10.7) 0.515 100 (11.5) 87 (10.0) 0.323
Midwest 261 (25.8) 1,265 (39.5) o0.001 248 (28.5) 245 (28.2) 0.870
South 528 (52.3) 1,260 (39.4) o0.001 425 (48.9) 427 (49.1) 0.924
West 106 (10.5) 334 (10.4) 0.958 96 (11.1) 110 (12.7) 0.305
Health plan type, n (%)
Commercial 692 (68.5) 1,231 (38.5) o0.001 559 (64.3) 566 (65.1) 0.691
MAPD 318 (31.5) 1,969 (61.5) o0.001 310 (35.7) 303 (34.9) 0.691
Time from ﬁrst AF claim to index
date, days, mean (SD)
8.9 (8.1) 8.4 (7.3) 0.084 8.7 (8.0) 8.4 (7.5) 0.343
Pre-index clinical indices
Deyo-Charlson comorbidity
index score, mean (SD)
1.73 (1.80) 2.49 (2.09) o0.001 1.85 (1.84) 1.86 (1.81) 0.967
CHADS2 score, mean (SD) 1.91 (1.24) 2.44 (1.30) o0.001 2.00 (1.24) 2.01 (1.21) 0.903
CHADS2 score group, n (%)
0 93 (9.2) 154 (4.8) o0.001 67 (7.7) 74 (8.5) 0.538
1 327 (32.4) 610 (19.1) o0.001 258 (29.7) 241 (27.7) 0.342
2-6 590 (58.4) 2,436 (76.1) o0.001 544 (62.6) 554 (63.8) 0.600
CHA2DS2-VASc score, mean
(SD)
3.09 (1.76) 3.95 (1.78) o0.001 3.23 (1.77) 3.26 (1.73) 0.749
HEMORR2HAGES score,
mean (SD)
2.28 (1.65) 3.14 (1.99) o0.001 2.41 (1.69) 2.33 (1.58) 0.320
HEMORR2HAGES score
group, n (%)
0-1 385 (38.2) 672 (21.0) o0.001 302 (34.8) 290 (33.4) 0.534
2-3 424 (42.0) 1,398 (43.7) 0.340 375 (43.2) 417 (48.0) 0.042
4-12 201 (19.9) 1,130 (35.3) o0.001 192 (22.1) 162 (18.6) 0.066
Elixhauser comorbidity index
score, mean (SD)
3.22 (2.07) 4.54 (2.43) o0.001 3.39 (2.09) 3.63 (2.19) 0.013
(continued)
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Table III. (continued).
Before PSM After PSM
Characteristic*
Dabigatran
(n¼1,010)
Warfarin
(n¼3,200) P value†
Dabigatran
(n¼869)
Warfarin
(n¼869) P value†
Pre-index conditions/events,
n (%)
Acute MI 66 (6.5) 272 (8.5) 0.045 64 (7.4) 64 (7.4) 1.000
Atrial ﬂutter 841 (83.3) 2,773 (86.7) 0.007 730 (84.0) 725 (83.4) 0.751
Bone marrow disease
(thrombocytopenia, chronic
anemia, myeloﬁbrosis)
40 (4.0) 251 (7.8) o0.001 39 (4.5) 38 (4.4) 0.909
Bleeding 55 (5.5) 340 (10.6) o0.001 54 (6.2) 35 (4.0) 0.037
Cancer 119 (11.8) 445 (13.9) 0.084
Cardiomyopathy 134 (13.3) 498 (15.6) 0.075 121 (13.9) 125 (14.4) 0.784
COPD/emphysema 180 (17.8) 644 (20.1) 0.108 153 (17.6) 171 (19.7) 0.272
Coagulopathy
(hemophilia, Von
Willebrand disease)
26 (2.6) 206 (6.4) o0.001 24 (2.8) 28 (3.2) 0.579
Coronary artery disease 374 (37.0) 1,363 (42.6) 0.002 338 (38.9) 331 (38.1) 0.727
Dyspepsia 13 (1.3) 47 (1.5) 0.671 12 (1.4) 13 (1.5) 0.842
Heart failure 244 (24.2) 1,256 (39.3) o0.001 237 (27.8) 243 (28.0) 0.737
Diabetes mellitus 304 (30.1) 1,184 (37.0) o0.001 271 (31.2) 258 (29.7) 0.495
HIV infection 2 (0.2) 4 (0.13) 0.592 1 (0.1) 1 (0.1) 1.000
Hyperlipidemia 699 (69.2) 2,248 (70.3) 0.529 605 (69.6) 590 (67.9) 0.444
Hypertension 127 (12.6) 605 (18.9) o0.001 114 (13.1) 105 (12.1) 0.520
Ischemic stroke 95 (9.4) 403 (12.6) 0.006 85 (9.8) 92 (10.6) 0.574
Liver disease 181 (17.9) 1,044 (32.6) o0.001 173 (19.9) 211 (24.3) 0.024
Left ventricular heart
failure
172 (17.0) 555 (17.3) 0.818 156 (18.0) 132 (15.2) 0.125
Multiple sclerosis 0 10 (0.3) 0.075 0 6 (0.7) -
Peptic ulcer/GERD 181 (17.9) 752 (23.5) o0.001 159 (18.3) 169 (19.5) 0.532
Peripheral artery disease 42 (4.2) 177 (5.5) 0.087 38 (4.4) 35 (4.0) 0.718
Renal disease 196 (19.4) 908 (28.4) o0.001 177 (20.4) 188 (21.6) 0.515
Rheumatoid arthritis 30 (3.0) 106 (3.3) 0.592 27 (3.1) 18 (2.1) 0.170
Transient ischemic attack 78 (7.7) 281 (8.8) 0.294 66 (7.6) 74 (8.5) 0.483
Venous thromboembolism 14 (1.4) 353 (11.0) o0.001 14 (1.6) 9 (1.0) 0.252
Pre-index medication use,
Anticoagulants, n (%)
Argatroban 0 1 (0.03) 0.574 0 0 –
Unfractionated Heparin
(Heparin)
35 (3.5) 162 (5.1) 0.036 32 (3.7) 30 (3.5) 0.793
Low Molecular Weight
Heparins:
Enoxaparin 38 (3.8) 200 (6.3) 0.003 37 (4.3) 37 (4.3) 1.000
Tinzaparin 0 0 – 0 0 –
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Table III. (continued).
Before PSM After PSM
Characteristic*
Dabigatran
(n¼1,010)
Warfarin
(n¼3,200) P value†
Dabigatran
(n¼869)
Warfarin
(n¼869) P value†
Dalteparin 2 (0.2) 15 (0.5) 0.237 2 (0.2) 1 (0.1) 0.564
Fondaparinux 1 (0.1) 8 (0.3) 0.365 1 (0.1) 1 (0.1) 1.000
Other medications, n (%)
Beta blockers (single
agent; i.e., no ﬁxed-dose
combinations)
513 (50.8) 1,551 (48.5) 0.198 433 (49.8) 448 (51.6) 0.492
Calcium channel
blockers (single agent;
i.e., no ﬁxed-dose
combinations)
317 (31.4) 1,026 (32.1) 0.688 271 (31.2) 265 (30.5) 0.761
Diuretics (single agent;
i.e., no ﬁxed-dose
combinations)
274 (27.1) 1,167 (36.5) o0.001 254 (29.2) 257 (29.6) 0.873
Other antihypertensives
(e.g., ACE inhibitors,
ARBs, ﬁxed-dose single
pill combinations)
579 (57.3) 1,938 (60.6) 0.067 509 (58.6) 501 (57.7) 0.697
Antihyperlipidemics 537 (53.2) 1,645 (51.4) 0.329 465 (53.5) 439 (50.2) 0.207
Corticosteroids 211 (20.9) 740 (23.1) 0.139 189 (21.8) 199 (22.9) 0.568
Antidiabetics 198 (19.6) 835 (26.1) o0.001 178 (20.5) 172 (19.8) 0.715
Antiarrhythmics
(Amiodarone,
Propafenone,
Flecainide,
Dronedarone, Sotalol,
dofetilide,
Disopyramide,
Quinidine)
98 (9.7) 150 (4.7) o0.001 72 (8.3) 68 (7.8) 0.715
Ketoconazole 20 (2.0) 56 (1.8) 0.632 17 (2.0) 20 (2.3) 0.622
Antiplatelets 120 (11.9) 414 (12.9) 0.379 101 (11.6) 110 (12.7) 0.511
Non-steroidal anti-
inﬂammatory drugs
240 (23.8) 706 (22.1) 0.259 201 (23.1) 206 (23.7) 0.775
Number of concomitant
medication classes,
mean (SD)
3.08 (1.88) 3.20 (1.99) 0.081 3.10 (1.91) 3.09 (1.99) 0.951
Index prescriber specialty, n (%)
Cardiology 427 (42.3) 693 (21.7) o0.001 323 (37.2) 310 (35.7) 0.479
Pulmonary medicine 6 (0.6) 26 (0.8) 0.486 6 (0.7) 9 (1.0) 0.439
Hematology 1 (0.1) 0 0.075 1 (0.1) 0 –
Internal medicine 171 (16.9) 868 (27.1) o0.001 161 (18.5) 153 (17.6) 0.600
Family/general practice 61 (6.0) 344 (10.8) o0.001 56 (6.4) 65 (7.5) 0.393
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Table III. (continued).
Before PSM After PSM
Characteristic*
Dabigatran
(n¼1,010)
Warfarin
(n¼3,200) P value†
Dabigatran
(n¼869)
Warfarin
(n¼869) P value†
Geriatrics 1 (0.1) 1 (0.03) 0.389 1 (0.1) 0 –
Surgery (all types, including
vascular surgery)
0 17 (0.5) 0.020 0 2 (0.2) –
Gastroenterolog 2 (0.2) 6 (0.2) 0.947 1 (0.1) 2 (0.2) 0.564
Neurology 3 (0.3) 11 (0.3) 0.822 3 (0.4) 2 (0.2) 0.655
Emergency medicine 0 16 (0.5) 0.024 0 5 (0.6) –
Other provider types 338 (33.5) 1,217 (38.0) 0.009 317 (36.5) 321 (36.9) 0.834
Unknown 0 0 – 0 0 –
Multiple 0 1 (0.03) 0.574 0 0 –
COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reﬂux disease; MAPD, Medicare Advantage with Part
D prescription drug coverage; MI, myocardial infarction; PSM, propensity score match; SD, standard deviation.
*The following pre-index variables were used for PSM: age, gender, plan type, geographic location, index month, Deyo-
Charlson comorbidity score, CHADS2 score, HEMORR2HAGES score, comorbidities (heart failure, diabetes, cardiomyopathy,
COPD/emphysema, hyperlipidemia, peptic ulcer/gastroesophageal reﬂux disease, stroke/transient ischemic attack,
hypertension, venous thromboembolism, bleeding), index prescriber specialty, time from ﬁrst AF claim to index exposure,
and concomitant medication use (argatroban, unfractionated heparin, enoxaparin, tinzaparin, dalteparin, fondaparinux, beta
blockers, calcium channel blockers, diuretics, other antihypertensives [angiotensin-converting-enzyme inhibitors, angiotensin
receptor blockers], antihyperlipidemics, corticosteroids, antidiabetics, antiarrhythmics [amiodarone, propafenone, ﬂecainide,
dronedarone, sotalol, dofetilide, disopyramide, quinidine], ketoconazole, antiplatelets, non-steroidal anti-inﬂammatory
drugs).
†2-sample t-test with Satterthwaite adjustment where appropriate (continuous variables) and chi-square test (categorical
variables).
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